Skip to content

Imaging Measures of Respiratory Health Registry

Imaging Measures of Respiratory Health Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05102825
Acronym
iMRH
Enrollment
1000
Registered
2021-11-02
Start date
2020-06-11
Completion date
2045-06-01
Last updated
2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Respiratory Disease

Brief summary

This is a prospective, observational cohort registry that aims to collect data on pulmonary structure and function in healthy people and those with respiratory disease, using structural and functional pulmonary 1H-MRI and hyperpolarized 129Xe-MRI. Outcome measures generated from MRI may include but are not limited to measures of regional ventilation, pulmonary microarchitecture, and regional gas exchange. Additionally, one of the goals of the registry is to facilitate the development of novel image analysis techniques that have not yet been invented. These data will be stored along with demographic data, clinical data, and pulmonary function testing (PFT) data. This is an open registry. Eligible local and international investigators/institutions can apply for access.

Interventions

DIAGNOSTIC_TEST1H and Xe-129 MRI

Traditional 1H-MRI (room air inhalation) and Xe-129 MRI (requires inhalation of Xenon 129 gas).

Sponsors

University of British Columbia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Years to 99 Years
Healthy volunteers
Yes

Inclusion criteria

Respiratory Disease Inclusion Criteria: 1. Physician-diagnosed lung disease - based on a diagnosis made by a treating staff physician and confirmed by the principal investigator. 2. Age 0-99 years. 3. Informed consent by participant, parent, or legal guardian 4. In the opinion of the Investigator, the participant will likely be able to perform maneuvers to obtain technically acceptable pulmonary XeMRI images.

Exclusion criteria

1. Physical findings at screening that, in the opinion of the Investigator, would compromise the safety of the participant or the quality of the research data. 2. Requirement of supplementary oxygen to maintain an oxygen saturation above 95%. 3. Failed MRI screening form. 4. History of claustrophobia. 5. Known current pregnancy or lactation. Healthy Inclusion Criteria: 1. Age 0-99 years 2. Informed consent by participant, parent, or legal guardian 3. In the opinion of the Investigator, the participant will likely be able to perform maneuvers to obtain technically acceptable pulmonary MRI images.

Design outcomes

Primary

MeasureTime frameDescription
Structural proton (1H) MRI datano predefined schedule in this open registry study; maximum 25 visits, over up to 25 yearsIncludes all proton MRI images collected to assess pulmonary structure. Data may be analysed qualitatively and quantitatively.
Functional proton (1H) MRI datano predefined schedule in this open registry study; maximum 25 visits, over up to 25 yearsIncludes all proton MRI images collected to assess pulmonary function. Data may be analysed qualitatively and quantitatively.
Functional hyperpolarized 129-xenon (129Xe) MRI datano predefined schedule in this open registry study; maximum 25 visits, over up to 25 yearsIncludes all proton images collected to assess pulmonary function. Data may be analysed qualitatively and quantitatively.

Secondary

MeasureTime frameDescription
Resting oxygen saturationno predefined schedule in this open registry study; maximum 25 visits, over up to 25 years
CFQ-R Respiratory domainno predefined schedule in this open registry study; maximum 25 visits, over up to 25 yearsOnly for participants with cystic fibrosis
St. George Respiratory Questionnaireno predefined schedule in this open registry study; maximum 25 visits, over up to 25 yearsOnly for participants with Respiratory disease.

Countries

Canada

Contacts

Primary ContactRodrigo Sandoval, MSc
Rodrigo.Sandoval@bcchr.ca6048752345

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026